Total pharma industry venture financing deals in April 2019 worth $1.05bn were announced in the US, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 22.4% over the previous month and a drop of 15% when compared with the last 12-month average of $1.24bn.
The US held a 67.8% share of the global pharma industry venture financing deal value that totalled $1.55bn in April 2019.
In terms of deal activity, the US recorded 58 deals during April 2019, marking a decrease of 20.6% over the previous month and a rise of 5.5% over the 12-month average.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe US pharma industry venture financing deals in April 2019: Top deals
The top five pharma industry venture financing deals accounted for 49.8% of the overall value during April 2019.
The combined value of the top five pharma industry venture financing deals stood at $524m, against the overall value of $1.05bn recorded for the month. The top announced pharma industry venture financing deal tracked by GlobalData in April 2019 was Aisling Capital, Boxer Capital, Longitude Capital Management Co, Malin Corporation, Novartis Pharma, Pentwater Capital Management, Perceptive Advisors and Vivo Capital’s $142m venture financing of Poseida Therapeutics.
In second place was the $125m venture financing of SpringWorks Therapeutics by ArrowMark Partners, Bain Capital, Boxer Capital, BVF Partners, GlaxoSmithKline, HBM Healthcare Investments, LifeArc, Orbimed Advisors, Perceptive Advisors, Pfizer Venture Investments, Samsara BioCapital and Surveyor Capital and in third place was Blackstone Life Sciences, Longitude Capital Management Co and Qiming Venture Partners USA’s $100m venture financing of Talaris Therapeutics.
The $82m venture financing of Vividion Therapeutics by Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, BVF Partners, Cardinal Partners, Casdin Capital, Celgene, Mirae Asset Capital, Mubadala Ventures, Nextech Invest, Trinitas Capital Management and Versant Venture Management and Advent Life Sciences, Alexandria Venture Investments, Canaan Partners, Celgene, GV Management Co, HBM Healthcare Investments, Henri Termeer, Nextech Invest, Omega Fund Management, Osage University Partners, Pfizer Venture Investments, venBio Partners and WuXi Healthcare Ventures’ venture financing of Arrakis Therapeutics for $75m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
